Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-Inclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 2021; Extension of Timeline To Finalize a Rulemaking, 58245-58246 [2021-22908]
Download as PDF
jspears on DSK121TN23PROD with PROPOSALS1
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Proposed Rules
podded bean legume vegetable subgroup
including: Asparagus bean, edible
podded at 1.5 ppm; catjang bean, edible
podded at 1.5 ppm; Chinese longbean,
edible podded at 1.5 ppm; cowpea,
edible podded at 1.5 ppm; French bean,
edible podded at 1.5 ppm; garden bean,
edible podded at 1.5 ppm; goa bean,
edible podded at 1.5 ppm; green bean,
edible podded at 1.5 ppm; guar bean,
edible podded at 1.5 ppm; jackbean,
edible podded at 1.5 ppm; kidney bean,
edible podded at 1.5 ppm; lablab bean,
edible podded at 1.5 ppm; moth bean,
edible podded at 1.5 ppm; mung bean,
edible podded at 1.5 ppm; navy bean,
edible podded at 1.5 ppm; rice bean,
edible podded at 1.5 ppm; scarlet
runner bean, edible podded at 1.5 ppm;
snap bean, edible podded at 1.5 ppm;
sword bean, edible podded at 1.5 ppm;
urd bean, edible podded at 1.5 ppm;
vegetable soybean, edible podded at 1.5
ppm; velvet bean, edible podded at 1.5
ppm; wax bean, edible podded at 1.5
ppm; winged pea, edible podded at 1.5
ppm; yardlong bean, edible podded at
1.5 ppm; individual crops of Proposed
Subgroup 6–18E: Dried shelled bean,
except soybean, subgroup including:
Adzuki bean, dry seed at 0.06 ppm;
African yam-bean, dry seed at 0.06 ppm;
American potato bean, dry seed at 0.06
ppm; Andean lupin bean, dry seed at
0.06 ppm; asparagus bean, dry seed at
0.06 ppm; black bean, dry seed at 0.06
ppm; blackeyed pea, dry seed at 0.06
ppm; blue lupin bean, dry seed at 0.06
ppm; broad bean, dry seed at 0.06 ppm;
catjang bean, dry seed at 0.06 ppm;
Chinese longbean, dry seed at 0.06 ppm;
cowpea, dry seed at 0.06 ppm; cranberry
bean, dry seed at 0.06 ppm; crowder
pea, dry seed at 0.06 ppm; dry bean, dry
seed at 0.06 ppm; field bean, dry seed
at 0.06 ppm; French bean, dry seed at
0.06 ppm; garden bean, dry seed at 0.06
ppm; goa bean, dry seed at 0.06 ppm;
grain lupin bean, dry seed at 0.06 ppm;
great northern bean, dry seed at 0.06
ppm; green bean, dry seed at 0.06 ppm;
guar bean, dry seed at 0.06 ppm; horse
gram, dry seed at 0.06 ppm; jackbean,
dry seed at 0.06 ppm; kidney bean, dry
seed at 0.06 ppm; lablab bean, dry seed
at 0.06 ppm; lima bean, dry seed at 0.06
ppm; morama bean, dry seed at 0.06
ppm; moth bean, dry seed at 0.06 ppm;
mung bean, dry seed at 0.06 ppm; navy
bean, dry seed at 0.06 ppm; pink bean,
dry seed at 0.06 ppm; pinto bean, dry
seed at 0.06 ppm; red bean, dry seed at
0.06 ppm; rice bean, dry seed at 0.06
ppm; scarlet runner bean, dry seed at
0.06 ppm; southern pea, dry seed at 0.06
ppm; sweet lupin bean, dry seed at 0.06
ppm; sword bean, dry seed at 0.06 ppm;
tepary bean, dry seed at 0.06 ppm; urd
VerDate Sep<11>2014
16:54 Oct 20, 2021
Jkt 256001
bean, dry seed at 0.06 ppm; vegetable
soybean, dry seed at 0.06 ppm; velvet
bean, dry seed at 0.06 ppm; white lupin
bean, dry seed at 0.06 ppm; white sweet
lupin bean, dry seed at 0.06 ppm;
winged pea, dry seed at 0.06 ppm;
yardlong bean, dry seed at 0.06 ppm;
yellow bean, dry seed at 0.06 ppm;
yellow lupin bean, dry seed at 0.06
ppm; and individual commodities of
Proposed Crop Subgroup 6–18F: Dried
shelled pea subgroup including:
Chickpea, dry seed at 0.2 ppm; dry pea,
dry seed at 0.2 ppm; field pea, dry seed
at 0.2 ppm; garden pea, dry seed at 0.2
ppm; grass-pea, dry seed at 0.2 ppm;
green pea, dry seed at 0.2 ppm; lentil,
dry seed at 0.2 ppm; pigeon pea, dry
seed at 0.2 ppm. A practical analytical
methodology for detecting and
measuring levels of trifloxystrobin in or
on raw agricultural commodities has
been submitted. Contact: RD.
8. PP 1F8930. (EPA–HQ–OPP–2021–
0624). Bayer CropScience LP, 800 N
Lindbergh Blvd., St. Louis, MO 63167,
requests to establish a tolerance in 40
CFR part 180 for residues of the
insecticide, Tetraniliprole [1-(3-chloro2-pyridinyl)-N-[4-cyano-2-methyl-6[(methylamino)carbonyl]phenyl]-3-[[5(trifluoromethyl)-2H-tetrazol-2yl]methyl]-1H-pyrazole-5-carboxamide],
in or on soybean: seed at 0.2 ppm; hulls
at 0.60 ppm; aspirated grain fractions at
45 ppm; hay at 0.20 ppm; and forage at
0.07 ppm. The high-performance liquid
chromatography-electrospray
ionization/tandem mass spectrometry
(LC/MS/MS) is used to measure and
evaluate the chemical Tetraniliprole.
Contact: RD.
9. PP 1F8930. (EPA–HQ–OPP–2021–
0624). Bayer CropScience LP, 800 N
Lindbergh Blvd., St. Louis, MO 63167,
requests to establish a tolerance in 40
CFR part 180 for residues of the
insecticide, Tetraniliprole [1-(3-chloro2-pyridinyl)-N-[4-cyano-2-methyl-6[(methylamino)carbonyl]phenyl]-3-[[5(trifluoromethyl)-2H-tetrazol-2yl]methyl]-1H-pyrazole-5-carboxamide],
in or on the raw agricultural
commodities of Crop Group 15; cereal
grains, except rice at 0.01 ppm and Crop
Group 16; forage, fodder, and straw of
cereal grains group, except field corn,
popcorn, and sweet corn at 0.1 ppm.
The high-performance liquid
chromatography-electrospray
ionization/tandem mass spectrometry
(LC/MS/MS) is used to measure and
evaluate the chemical Tetraniliprole.
Contact: RD.
Authority: 21 U.S.C. 346a.
PO 00000
Frm 00020
Fmt 4702
Sfmt 4702
58245
Dated: October 13, 2021.
Delores Barber,
Director, Information Technology and
Resources Management Division, Office of
Program Support.
[FR Doc. 2021–22970 Filed 10–20–21; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Parts 422, 423, 438, and 498
[CMS–4185–RCN]
RIN 0938–AK02
Medicare and Medicaid Programs;
Policy and Technical Changes to the
Medicare Advantage, Medicare
Prescription Drug Benefit, Program of
All-Inclusive Care for the Elderly
(PACE), Medicaid Fee-For-Service, and
Medicaid Managed Care Programs for
Years 2020 and 2021; Extension of
Timeline To Finalize a Rulemaking
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Extension of timeline.
AGENCY:
The Social Security Act (the
Act) requires us to publish a Medicare
final rule no later than 3 years after the
publication date of the proposed rule.
This document announces an extension
of the timeline for publication of a
Medicare final rule in accordance with
the Act, which allows us to extend the
timeline for publication of the
‘‘Medicare and Medicaid Programs;
Policy and Technical Changes to the
Medicare Advantage, Medicare
Prescription Drug Benefit, Program of
All-inclusive Care for the Elderly
(PACE), Medicaid Fee-For-Service, and
Medicaid Managed Care Programs for
Years 2020 and 2021’’ final rule under
exceptional circumstances.
DATES: As of October 21, 2021, the
timeline for publication of a rule to
finalize the November 1, 2018 proposed
rule (83 FR 54982) is extended until
November 1, 2022.
FOR FURTHER INFORMATION CONTACT:
Joseph Strazzire, (410) 786–2775.
SUPPLEMENTARY INFORMATION: On
November 1, 2018 (83 FR 54982), we
published a proposed rule, ‘‘Medicare
and Medicaid Programs; Policy and
Technical Changes to the Medicare
Advantage, Medicare Prescription Drug
Benefit, Program of All-inclusive Care
for the Elderly (PACE), Medicaid FeeSUMMARY:
E:\FR\FM\21OCP1.SGM
21OCP1
58246
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Proposed Rules
jspears on DSK121TN23PROD with PROPOSALS1
For-Service, and Medicaid Managed
Care Programs for Years 2020 and
2021,’’ that would revise the Medicare
Advantage (MA) Risk Adjustment Data
Validation (RADV) regulations to
improve program efficiency and
payment accuracy. The proposed rule
discussed the Secretary’s authority to:
(1) Extrapolate in the recovery of RADV
overpayments, starting with payment
year 2011 contract-level audits; and (2)
not apply a fee-for-service (FFS) adjuster
to the RADV overpayment
determinations.
Section 1871(a)(3)(A) of the Act
requires the Secretary to establish and
publish a regular timeline for the
publication of final regulations based on
the previous publication of a proposed
regulation. In accordance with section
1871(a)(3)(B) of the Act, the timeline
may vary among different regulations
based on differences in the complexity
of the regulation, the number and scope
of comments received, and other
relevant factors, but may not be longer
than 3 years except under exceptional
circumstances. In addition, in
accordance with section 1871(a)(3)(B) of
the Act, the Secretary may extend the
VerDate Sep<11>2014
16:54 Oct 20, 2021
Jkt 256001
initial targeted publication date of the
final regulation if the Secretary, no later
than the regulation’s previously
established proposed publication date,
publishes a notice with the new target
date for publication, and such notice
includes a brief explanation of the
justification for the variation.
The final rule for the November 1,
2018 proposed rule should be published
by November 1, 2021. However, we are
unable to meet the 3-year timeline for
publication of the previously referenced
RADV-audit related provisions because
of exceptional circumstances.
Specifically, on October 26, 2018, just
prior to the publication of the proposed
rule, we published the FFS Adjuster
Study. On December 27, 2018, we
announced an extension of the comment
period for the proposed RADV
provisions of the rule until April 30,
2019 and a plan to release data
underlying the FFS Adjuster study. On
March 6, 2019 we announced the
release of data underlying the FFS
Adjuster study. On April 30, 2019, we
announced an additional extension of
the comment period for the RADV
provision until August 28, 2019. We
PO 00000
Frm 00021
Fmt 4702
Sfmt 9990
also announced that we would be
releasing additional data underlying the
FFS Adjuster Study, including
additional data containing Protected
Health Information, to all parties who
entered an applicable data use
agreement and paid the required fee.
Finally, on June 28, 2019, we released
additional material related to the FFS
Adjuster Study, and made a further
request for public comment. Based on
extensive public comments received on
the proposed rule and subsequent FFS
Adjuster study and related data along
with delays resulting from the agency’s
focus on the COVID–19 public health
emergency, we determined that
additional time is needed to address the
complex policy and operational issues
that were raised.
This document extends the timeline
for publication of the final rule for 1
year, until November 1, 2022.
Karuna Seshasai,
Executive Secretary to the Department,
Department of Health and Human Services.
[FR Doc. 2021–22908 Filed 10–20–21; 8:45 am]
BILLING CODE 4120–01–P
E:\FR\FM\21OCP1.SGM
21OCP1
Agencies
[Federal Register Volume 86, Number 201 (Thursday, October 21, 2021)]
[Proposed Rules]
[Pages 58245-58246]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-22908]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 422, 423, 438, and 498
[CMS-4185-RCN]
RIN 0938-AK02
Medicare and Medicaid Programs; Policy and Technical Changes to
the Medicare Advantage, Medicare Prescription Drug Benefit, Program of
All-Inclusive Care for the Elderly (PACE), Medicaid Fee-For-Service,
and Medicaid Managed Care Programs for Years 2020 and 2021; Extension
of Timeline To Finalize a Rulemaking
AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of
Health and Human Services (HHS).
ACTION: Extension of timeline.
-----------------------------------------------------------------------
SUMMARY: The Social Security Act (the Act) requires us to publish a
Medicare final rule no later than 3 years after the publication date of
the proposed rule. This document announces an extension of the timeline
for publication of a Medicare final rule in accordance with the Act,
which allows us to extend the timeline for publication of the
``Medicare and Medicaid Programs; Policy and Technical Changes to the
Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-
inclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and
Medicaid Managed Care Programs for Years 2020 and 2021'' final rule
under exceptional circumstances.
DATES: As of October 21, 2021, the timeline for publication of a rule
to finalize the November 1, 2018 proposed rule (83 FR 54982) is
extended until November 1, 2022.
FOR FURTHER INFORMATION CONTACT: Joseph Strazzire, (410) 786-2775.
SUPPLEMENTARY INFORMATION: On November 1, 2018 (83 FR 54982), we
published a proposed rule, ``Medicare and Medicaid Programs; Policy and
Technical Changes to the Medicare Advantage, Medicare Prescription Drug
Benefit, Program of All-inclusive Care for the Elderly (PACE), Medicaid
Fee-
[[Page 58246]]
For-Service, and Medicaid Managed Care Programs for Years 2020 and
2021,'' that would revise the Medicare Advantage (MA) Risk Adjustment
Data Validation (RADV) regulations to improve program efficiency and
payment accuracy. The proposed rule discussed the Secretary's authority
to: (1) Extrapolate in the recovery of RADV overpayments, starting with
payment year 2011 contract-level audits; and (2) not apply a fee-for-
service (FFS) adjuster to the RADV overpayment determinations.
Section 1871(a)(3)(A) of the Act requires the Secretary to
establish and publish a regular timeline for the publication of final
regulations based on the previous publication of a proposed regulation.
In accordance with section 1871(a)(3)(B) of the Act, the timeline may
vary among different regulations based on differences in the complexity
of the regulation, the number and scope of comments received, and other
relevant factors, but may not be longer than 3 years except under
exceptional circumstances. In addition, in accordance with section
1871(a)(3)(B) of the Act, the Secretary may extend the initial targeted
publication date of the final regulation if the Secretary, no later
than the regulation's previously established proposed publication date,
publishes a notice with the new target date for publication, and such
notice includes a brief explanation of the justification for the
variation.
The final rule for the November 1, 2018 proposed rule should be
published by November 1, 2021. However, we are unable to meet the 3-
year timeline for publication of the previously referenced RADV-audit
related provisions because of exceptional circumstances. Specifically,
on October 26, 2018, just prior to the publication of the proposed
rule, we published the FFS Adjuster Study. On December 27, 2018, we
announced an extension of the comment period for the proposed RADV
provisions of the rule until April 30, 2019 and a plan to release data
underlying the FFS Adjuster study. On March 6, 2019 we announced the
release of data underlying the FFS Adjuster study. On April 30, 2019,
we announced an additional extension of the comment period for the RADV
provision until August 28, 2019. We also announced that we would be
releasing additional data underlying the FFS Adjuster Study, including
additional data containing Protected Health Information, to all parties
who entered an applicable data use agreement and paid the required fee.
Finally, on June 28, 2019, we released additional material related to
the FFS Adjuster Study, and made a further request for public comment.
Based on extensive public comments received on the proposed rule and
subsequent FFS Adjuster study and related data along with delays
resulting from the agency's focus on the COVID-19 public health
emergency, we determined that additional time is needed to address the
complex policy and operational issues that were raised.
This document extends the timeline for publication of the final
rule for 1 year, until November 1, 2022.
Karuna Seshasai,
Executive Secretary to the Department, Department of Health and Human
Services.
[FR Doc. 2021-22908 Filed 10-20-21; 8:45 am]
BILLING CODE 4120-01-P